Molindone

Last updated

Molindone
Molindone.svg
Clinical data
Pronunciation /moʊˈlɪndoʊn/ moh-LIN-dohn
Trade names Moban
Other namesEN-1733 A; EN1773-A; EN1773A
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682238
Pregnancy
category
  • C
Routes of
administration 		By mouth (tablets) [1]
Drug class Typical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic
Elimination half-life 2 hours [2]
Duration of action 24–36 hours [1]
Excretion Minor, renal and fecal [1]
Identifiers
  • 3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-
    1,5,6,7-tetrahydro-4H-indol-4-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.254.109 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H24N2O2
Molar mass 276.380 g·mol−1
3D model (JSmol)
  • O=C2c1c(c([nH]c1CCC2CN3CCOCC3)C)CC
  • InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3 Yes check.svgY
  • Key:KLPWJLBORRMFGK-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Molindone, sold under the brand name Moban, is an antipsychotic medication which is used in the United States in the treatment of schizophrenia. [2] [1] [3] [4] It is taken by mouth. [1] [2]

Contents

Side effects of molindone include extrapyramidal symptoms and tardive dyskinesia, among others. [2] [1] Molindone is thought to work by blocking the effects of dopamine in the brain, leading to diminished symptoms of psychosis. [2] The drug is sometimes described as a typical antipsychotic, [5] and sometimes described as an atypical antipsychotic. [6] Chemically, molindone is an indole and is structurally distinct from many other antipsychotics. [2]

Molindone was first described by 1966 [7] and was introduced for medical use in 1974. [8] It remains marketed only in the United States. [9] The drug has been repurposed and is being developed for potential treatment of aggression in children and adolescents with attention deficit hyperactivity disorder (ADHD). [10] [11] [12]

Medical uses

Molindone is used in the treatment of schizophrenia. [2] [1]

Available forms

Molindone is available in the form of 5, 10, 25, and 50 mg oral tablets. [1]

Adverse effects

The side effect profile of molindone is similar to that of other typical antipsychotics. This includes extrapyramidal symptoms and tardive dyskinesia. [2] [1] Unlike most antipsychotics, however, molindone use is associated with decreased appetite and weight loss rather than with weight gain. [6] [13] Molindone may have less potential for sedation than certain other antipsychotics owing to its lack of antihistamine activity. [2] It has little or no anticholinergic activity and may be less likely than certain other antipsychotics to cause orthostatic hypotension. [2]

Pharmacology

Pharmacodynamics

Molindone is known to act as a potent antagonist of the dopamine D2 receptor (IC50 Tooltip half-maximal inhibitory concentration = 84–140 nM) and of the serotonin 5-HT2B receptor (IC50 = 410 nM). [10] [14] It is far less potent as an antagonist of the dopamine D1, D3, and D5 receptors (IC50 = 3,200–8,300 nM) and of the serotonin 5-HT2A receptor (IC50 = 14,000 nM). [14] The drug does not significantly bind to or inhibit the α-adrenergic receptors, nor does it affect various other receptors, such as the serotonin 5-HT1A, 5-HT2C, 5-HT6, and 5-HT7 receptors. [14] [2] Likewise, molindone has essentially no affinity for the muscarinic acetylcholine receptors and has very little affinity for the histamine H1 receptor or the α1-adrenergic receptor. [2] However, it has been found to have intermediate affinity for the α2-adrenergic receptor. [2] The metabolites of molindone appear to be largely inactive in vitro . [14] The preceding findings suggest that molindone is pharmacologically distinct from most atypical antipsychotics, which act as potent antagonists of both the D2 and 5-HT2A receptors. [14]

Additional binding data on molindone are also available and in some cases have found contrasting results relative to the above findings, for instance high affinity for the dopamine D3 receptor. [15] [16]

Molindone is described as an antipsychotic, sedative, and major tranquilizer. [7] In animals, it reduces spontaneous locomotor activity, inhibits conditioned avoidance responses, produces catalepsy and hypothermia, and limits aggression in monkeys. [2] [1] Like other antipsychotics, molindone antagonizes the effects of the dopamine releasing agent amphetamine and the dopamine receptor agonist apomorphine. [2] [1] In contrast to many antipsychotics however, molindone shows antidepressant-like effects in animals, for example reversing ptosis induced by the dopamine depleting agent tetrabenazine, potentiating 5-hydroxytryptophan (5-HTP)-induced tremors, and potentiating certain effects of levodopa (L-DOPA). [2] [1] It shows little anticholinergic activity in animals and its lack of histamine H1 receptor antagonism suggests less potential for sedation and weight gain than certain other antipsychotics. [2] The drug shows antiemetic effects in animals. [1]

Molindone has been reported to inhibit monoamine oxidase both in vitro and in vivo . [2] However, very high concentrations (~100,000 nM) and high doses (10 and 40 mg/kg) are required for monoamine oxidase inhibition. [2] Its inhibition of monoamine oxidase is irreversible and is selective for monoamine oxidase A (MAO-A). [2] The drug is much more potent in inhibiting monoamine oxidase in vivo than in vitro, suggesting that an active metabolite may be responsible for its monoamine oxidase inhibition. [2] The MAO-A inhibition of molindone may be responsible for its antidepressant-like effects in animals. [2] It is unclear whether the monoamine oxidase inhibition of molindone observed in preclinical research occurs therapeutically in humans or is clinically significant. [2]

It has no affinity for the muscariniac acetylcholine receptors. [17]

Pharmacokinetics

The elimination half-life of molindone is approximately 2 hours. [2] This half-life is much shorter than that of most other antipsychotics. [2] Concentrations of molindone are negligible 12 hours following the last dose even it is used at high doses. [2] Lithium has been found to prolong the half-life of molindone by at least 4-fold. [2] In spite of the preceding findings, the duration of action of molindone is 24 to 36 hours. [2] [1] It has been suggested that the antipsychotic effects of molindone may be mediated by active metabolites rather than by molindone itself. [2]

Chemistry

Molindone is an indole derivative or dihydroindole and is structurally distinct from many other antipsychotics. [2] [1]

Analogues

Some structurally related compounds include L-741,626, losindole, and piquindone. Other indole-containing antipsychotics include ciclindole, flucindole, roxindole, sertindole, and tepirindole.

Synthesis

Patent: Newer patent: Molindone synthesis.svg
Patent: Newer patent:

Condensation of oximinoketone 2 (from nitrosation of 3-pentanone), with cyclohexane-1,3-dione (1) in the presence of zinc and acetic acid leads directly to the partly reduced indole derivative 6. The transformation may be rationalized by assuming as the first step, reduction of 2 to the corresponding α-aminoketone. Conjugate addition of the amine to 1 followed by elimination of hydroxide (as water) would give ene-aminoketone 3. This enamine may be assumed to be in tautomeric equilibrium with imine 4. Aldol condensation of the side chain carbonyl group with the doubly activated ring methylene group would then result in cyclization to pyrrole 5; simple tautomeric transformation would then give the observed product. Mannich reaction of 6 with formaldehyde and morpholine gives the tranquilizer molindone (7).

History

Molindone was first described in the literature by 1966. [7] [21] [22] It was first approved for medical use, to treat schizophrenia, in 1974 in the United States. [8]

Society and culture

Availability

Molindone has been marketed in the United States, Finland, and Hong Kong. [23] In 2000, it was available only in these three countries. [23] By 2017, molindone continued to be marketed only in the United States. [9]

The drug was discontinued by its original supplier, Endo Pharmaceuticals, on January 13, 2010. [24] After having been produced and subsequently discontinued by Core Pharma in 2015 to 2017, molindone is available again from Epic Pharma effective December 2018. [25]

Research

Depression and anxiety

Molindone has been studied in the treatment of depression and anxiety. [2] Some antidepressant and anxiolytic effects have been observed in small and old clinical studies, but findings in terms of effectiveness were mixed. [2]

Aggression in children and adolescents

Molindone was found to reduce aggressive symptoms, including agitation, hostility, and uncooperativeness, in adults with schizophrenia in the 1970s. [26] Many other antipsychotics have also shown clinical anti-aggressive effects. [26] Subsequently, molindone was found to potentially be effective in the treatment of hospitalized aggressive children with conduct disorder in a clinical trial comparing it with thioridazine in the 1980s. [10] [11] [27] This study eventually led to molindone being developed for treatment of impulsive aggression in youth much later on. [10]

Low-dose extended-release molindone (developmental code name SPN-810) is under development for the treatment of impulsive aggression in children and adolescents with attention deficit hyperactivity disorder (ADHD). [12] [10] As of May 2024, it is in phase 3 clinical trials for this indication. [12] Negative effectiveness findings in a phase 3 trial have been reported. [12] The exact mechanism of action of molindone for this indication is unknown, but has been proposed to be related to dopamine D2 and serotonin 5-HT2B receptor antagonism. [10] [14]

Related Research Articles

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Mirtazapine</span> Antidepressant medication

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks but can also manifest as early as one to two weeks. It is often used in cases of depression complicated by anxiety or insomnia. The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants. It is taken by mouth.

α-Ethyltryptamine Chemical compound

α-Ethyltryptamine, also known as etryptamine, is an entactogen and stimulant drug of the tryptamine family. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s before being withdrawn due to toxicity.

<span class="mw-page-title-main">Amoxapine</span> Tricyclic antidepressant medication

Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1980, approximately 10 to 20 years after most of the other TCAs were introduced in the United States.

<span class="mw-page-title-main">Imipramine</span> Antidepressant

Imipramine, sold under the brand name Tofranil, among others, is a tricyclic antidepressant (TCA) mainly used in the treatment of depression. It is also effective in treating anxiety and panic disorder. Imipramine is taken by mouth.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Tiotixene</span> Typical antipsychotic medication

Tiotixene, or thiothixene is a typical antipsychotic agent currently sold under the brand name Navane which is predominantly utilised to treat acute and chronic schizophrenia. Beyond its primary indication, it can exhibit a variety of effects common to neuroleptic drugs including anxiolytic, anti-depressive, and anti-aggressive properties.

<span class="mw-page-title-main">Tetrabenazine</span> Medication for hyperkinetic movement disorders

Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off label," tetrabenazine was the first approved treatment for Huntington's disease in the U.S. The compound has been known since the 1950s.

<span class="mw-page-title-main">Trimipramine</span> Antidepressant

Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or "second-generation" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine", a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain.

<span class="mw-page-title-main">Chlorprothixene</span> Typical antipsychotic medication

Chlorprothixene, sold under the brand name Truxal among others, is a typical antipsychotic of the thioxanthene group.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride, sold under the brand names Solian and Barhemsys, is a medication used in the treatment of schizophrenia, acute psychotic episodes, depression, and nausea and vomiting. It is specifically used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; at low doses by mouth to treat depression; and at higher doses by mouth to treat psychosis.

Extrapyramidal symptoms (EPS) are symptoms that are archetypically associated with the extrapyramidal system of the brain's cerebral cortex. When such symptoms are caused by medications or other drugs, they are also known as extrapyramidal side effects (EPSE). The symptoms can be acute (short-term) or chronic (long-term). They include movement dysfunction such as dystonia, akathisia, parkinsonism characteristic symptoms such as rigidity, bradykinesia, tremor, and tardive dyskinesia. Extrapyramidal symptoms are a reason why subjects drop out of clinical trials of antipsychotics; of the 213 (14.6%) subjects that dropped out of one of the largest clinical trials of antipsychotics, 58 (27.2%) of those discontinuations were due to EPS.

<span class="mw-page-title-main">Opipramol</span> Drug used to treat depressive and anxiety disorders

Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. Despite chemically being a tricyclic dibenzazepine (iminostilbene) derivative similar to imipramine, opipramol is not a monoamine reuptake inhibitor like most other tricyclic antidepressants, and instead, uniquely among antidepressants, acts primarily as a SIGMAR1 agonist. It was developed by Schindler and Blattner in 1961.

<span class="mw-page-title-main">Pipamperone</span> Antipsychotic drug

Pipamperone, sold under the brand name Dipiperon, is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia and as a sleep aid for depression. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.

<span class="mw-page-title-main">Roxindole</span> Dopaminergic & serotonergic drug developed for schizophrenia treatment

Roxindole (EMD-49,980) is a dopaminergic and serotonergic drug which was originally developed by Merck KGaA for the treatment of schizophrenia. In clinical trials its antipsychotic efficacy was only modest but it was unexpectedly found to produce potent and rapid antidepressant and anxiolytic effects. As a result, roxindole was further researched for the treatment of depression instead. It has also been investigated as a therapy for Parkinson's disease and prolactinoma.

<span class="mw-page-title-main">Clocapramine</span> Antipsychotic medication

Clocapramine, also known as 3-chlorocarpipramine, is an atypical antipsychotic of the iminostilbene class which was introduced in Japan in 1974 by Yoshitomi for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017111s066lbl.pdf
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Owen RR, Cole JO (August 1989). "Molindone hydrochloride: a review of laboratory and clinical findings". J Clin Psychopharmacol. 9 (4): 268–276. doi:10.1097/00004714-198908000-00006. PMID   2671060.
  3. ↑ "molindone". F.A. Davis Company.
  4. ↑ "Molindone".
  5. ↑ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID   19028375.
  6. 1 2 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall AM (ed.). "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID   17253473.
  7. 1 2 3 Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 834. ISBN   978-1-4757-2085-3 . Retrieved 18 October 2024.
  8. 1 2 National Archives (U.S.) (2013). Federal Register (in German). Office of the Federal Register, National Archives and Records Service, General Services Administration. p. 66742. Retrieved 18 October 2024.
  9. 1 2 "Molindone Uses, Side Effects & Warnings". Archived from the original on 2017-09-27.
  10. 1 2 3 4 5 6 Robb AS, Schwabe S, Ceresoli-Borroni G, Nasser A, Yu C, Marcus R, Candler SA, Findling RL (March 2019). "A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression". Postgrad Med. 131 (2): 129–137. doi: 10.1080/00325481.2019.1574401 . PMID   30678534.
  11. 1 2 Balia C, Carucci S, Coghill D, Zuddas A (August 2018). "The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication?". Neurosci Biobehav Rev. 91: 218–238. doi:10.1016/j.neubiorev.2017.01.024. PMID   28137460.
  12. 1 2 3 4 "Molindone - Supernus Pharmaceuticals". AdisInsight. 29 May 2024. Retrieved 18 October 2024.
  13. ↑ Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (November 1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". The American Journal of Psychiatry. 156 (11): 1686–1696. doi:10.1176/ajp.156.11.1686. PMID   10553730. S2CID   38635470.
  14. 1 2 3 4 5 6 Yu C, Gopalakrishnan G (2018). "In vitro pharmacological characterization of SPN-810M (molindone)". J Exp Pharmacol. 10: 65–73. doi: 10.2147/JEP.S180777 . PMC   6254985 . PMID   30538587.
  15. ↑ Liu T. "BindingDB BDBM50130290 3-Ethyl-2-methyl-5-morpholin-4-ylmethyl-1,5,6,7-tetrahydro-indol-4-one::3-Ethyl-2-methyl-5-morpholin-4-ylmethyl-1,5,6,7-tetrahydro-indol-4-one ( Molindone)::CHEMBL460::MOLINDONE::Moban". BindingDB. Retrieved 18 October 2024.
  16. ↑ "PDSP Database". UNC (in Zulu). Retrieved 18 October 2024.
  17. ↑ Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM (January 2023). "A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity". Pharmaceutics. 15 (1): 230. doi: 10.3390/pharmaceutics15010230 . PMC   9863833 . PMID   36678858.
  18. ↑ SCHOEN KARL, J PACHTER IRWIN; BE 670798 (1965 to Endo Lab).
  19. ↑ Irwin J Pachter, Karl Schoen, U.S. patent 3,491,093 (1970 to Endo Lab).
  20. ↑ Martin Hanbauer, et al. WO2014042688 (Supernus Pharmaceuticals Inc).
  21. ↑ Rubin AA, Yen HC, Pfeffer M (November 1967). "Psychopharmacological profile of molindone". Nature. 216 (5115): 578–579. Bibcode:1967Natur.216..578R. doi:10.1038/216578a0. PMID   4966848.
  22. ↑ Sugerman AA, Herrmann J (1967). "Molindone: an indole derivative with antipsychotic activity". Clin Pharmacol Ther. 8 (2): 261–265. doi:10.1002/cpt196782261. PMID   6021585.
  23. 1 2 Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 700. ISBN   978-3-88763-075-1 . Retrieved 18 October 2024.
  24. ↑ "Drugs to be Discontinued". www.fda.gov. Archived from the original on 2009-06-03.
  25. ↑ "NEWS". www.epic-pharma.com. Retrieved 2018-12-12.
  26. 1 2 Itil TM, Wadud A (February 1975). "Treatment of human aggression with major tranquilizers, antidepressants, and newer psychotropic drugs". J Nerv Ment Dis. 160 (2–1): 83–99. doi:10.1097/00005053-197502000-00003. PMID   235010.
  27. ↑ Greenhill LL, Solomon M, Pleak R, Ambrosini P (August 1985). "Molindone hydrochloride treatment of hospitalized children with conduct disorder". J Clin Psychiatry. 46 (8 Pt 2): 20–25. PMID   3894338.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.